Product

odetiglucan

1 clinical trial

1 indication

Indication

Pancreatic Cancer

Clinical trial

P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo

Status: Terminated, Estimated PCD: 2024-03-04